Perrigo Commences Shipments Of Opill To Retailers Nationwide
Portfolio Pulse from Benzinga Newsdesk
Perrigo Company plc (NYSE:PRGO) has announced the commencement of shipments of Opill®, the first daily birth control pill available without a prescription in the U.S., to retailers nationwide. Opill® will be available for pre-order and in-store in the coming weeks. Approved by the FDA in July 2023, Opill® aims to improve accessibility and affordability of birth control, with prices ranging from $19.99 for a one-month supply to $89.99 for a six-month supply. Perrigo emphasizes the importance of this milestone in reproductive health and has also planned a cost-assistance program for low-income individuals.
March 04, 2024 | 1:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Perrigo's launch of Opill®, the first OTC daily birth control pill in the U.S., represents a significant milestone in reproductive health, potentially increasing the company's market presence and consumer base.
The introduction of Opill® by Perrigo as the first OTC daily birth control pill in the U.S. is a groundbreaking development in reproductive health, likely to attract significant consumer interest and potentially increase Perrigo's market share in the consumer self-care sector. The FDA approval and the strategic pricing, along with a cost-assistance program for low-income individuals, are likely to enhance the product's accessibility and affordability, positively impacting Perrigo's brand reputation and financial performance in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100